Drug Type Trispecific T-cell engager (TriTE) |
Synonyms CC312 |
Target |
Action inhibitors, agonists, stimulants |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Scleroderma, Diffuse | Phase 1 | China | 30 Sep 2025 | |
| Systemic Lupus Erythematosus | Phase 1 | China | 11 Sep 2025 | |
| Evans Syndrome | Phase 1 | China | 08 Nov 2024 | |
| Idiopathic Inflammatory Myopathies | Phase 1 | China | 08 Nov 2024 | |
| Purpura, Thrombocytopenic, Idiopathic | Phase 1 | China | 08 Nov 2024 | |
| Rheumatoid Arthritis | Phase 1 | China | 08 Nov 2024 | |
| Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 07 Aug 2023 | |
| B-cell lymphoma refractory | Phase 1 | China | 07 Aug 2023 | |
| B-Cell Malignant Neoplasm | Phase 1 | China | 07 Aug 2023 | |
| CD19 Positive B-Cell Leukemia | Phase 1 | China | 07 Aug 2023 |






